References

Evaluation of candidate theranostics for227Th/89Zr paired radioimmunotherapy of lymphoma

10.2967/jnumed.122.264979 · 2023 · External reference

10.1080/19420862.2016.1185581

10.1080/19420862.2016.1185581 · External reference

Site-specific 89Zr- and 111In-radiolabeling and in vivo evaluation of glycan-free antibodies by azide–alkyne cycloaddition with a non-natural amino acid

10.1021/acs.bioconjchem.0c00100 · 2020 · External reference

Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy

10.1016/j.jconrel.2025.02.047 · 2025 · External reference

Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab′)2—A phase I study

10.2967/jnumed.109.062604 · 2009 · External reference

Zirconium 89 and copper 64 for ImmunoPET: from antibody bioconjugation and radiolabeling to molecular imaging

10.3390/pharmaceutics16070882 · 2024 · External reference

Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models

10.1038/s41598-024-70385-8 · 2024 · External reference

10.3390/ph11040132

10.3390/ph11040132 · External reference

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

10.1007/s00259-018-4099-8 · 2018 · External reference

Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer

10.1097/mnm.0b013e328365d99b · 2013 · External reference

Actinium-225 targeted alpha particle therapy for prostate cancer

10.7150/thno.96403 · 2024 · External reference

Unresolved reference

2016 · External reference

Synthesis and evaluation of HOPO-O8-methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates

10.1016/j.jinorgbio.2025.113077 · 2026 · External reference

124I-huA33 antibody PET of colorectal cancer

10.2967/jnumed.110.086165 · 2011 · External reference

Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

10.7150/thno.48810 · 2020 · External reference

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma

10.7150/thno.26585 · 2018 · External reference

Versatile bifunctional PYTA derivatives for 225Ac radiolabeling: a comparison to gold standards

10.2967/jnumed.125.270234 · 2025 · External reference

Optimized clinical performance of growth hormone with an expanded genetic code

10.1073/pnas.1100387108 · 2011 · External reference

Head-to-head comparison of dFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET

10.1007/s00259-020-05002-7 · 2021 · External reference

Toward personalized medicine: one chelator for imaging and therapy with lutetium-177 and actinium-225

10.1021/jacs.2c08438 · 2022 · External reference

Consensus nomenclature rules for radiopharmaceutical chemistry — setting the record straight

10.1016/j.nucmedbio.2017.09.004 · 2017 · External reference

10.1186/s41181-018-0047-y

10.1186/s41181-018-0047-y · External reference

10.2967/jnumed.120.255679

10.2967/jnumed.120.255679 · External reference

Site-specific photoaffinity bioconjugation for the creation of 89Zr-labeled radioimmunoconjugates

10.1007/s11307-023-01818-5 · 2023 · External reference

Radioactive drugs emerge from the shadows to storm the market

10.1038/nbt1218-1125 · 2018 · External reference

Perspectives on internal dosimetry for optimized radionuclide therapy

2022 · External reference

177Lu-PSMA-617 single-photon emission computed tomography/computed tomography dosimetry and radiobiological models demonstrate decreasing tumor-to-kidney dose ratio with successive cycles

10.1016/j.ijrobp.2025.06.3869 · 2025 · External reference

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

10.1182/blood-2003-09-3284 · 2004 · External reference

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

10.1182/blood-2017-09-807610 · 2018 · External reference

Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma

10.1093/annonc/mdi148 · 2005 · External reference

Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses

10.2967/jnumed.115.163824 · 2016 · External reference

Preliminary development and testing of c595 radioimmunoconjugates for targeting MUC1 cancer epitopes in pancreatic ductal adenocarcinoma

2022 · External reference

Site‐specific and stoichiometric modification of antibodies by bacterial transglutaminase

10.1002/anie.201004243 · 2010 · External reference

H2BZmacropa-NCS: a bifunctional chelator for actinium-225 targeted alpha therapy

10.1021/acs.bioconjchem.2c00190 · 2022 · External reference

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies

10.1016/j.nucmedbio.2013.01.012 · 2013 · External reference

Dual radionuclide theranostic pretargeting

10.1021/acs.molpharmaceut.9b00746 · 2019 · External reference

Tumor targeting by a multivalent single-chain Fv (scFv) anti-lewis Y antibody construct

2008 · External reference

Scaling-down antibody radiolabeling reactions with zirconium-89

10.1039/c5dt04774a · 2016 · External reference

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-hodgkin lymphoma

10.1182/bloodadvances.2020002583 · 2020 · External reference

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

10.1182/bloodadvances.2020002603 · 2020 · External reference

Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model

10.7150/thno.32883 · 2019 · External reference

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5

10.1074/jbc.m604127200 · 2006 · External reference

Exploration of radionuclide labeling of a novel scFv-fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment

10.1016/j.ejmech.2024.116134 · 2024 · External reference

Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging

10.1021/bc100464e · 2011 · External reference

10.1021/acs.bioconjchem.0c00171

10.1021/acs.bioconjchem.0c00171 · External reference

Synthesis of novel DOTA-/AAZTA-based bifunctional chelators: solution thermodynamics, peptidomimetic conjugation, and radiopharmaceutical evaluation

10.1016/j.biopha.2023.115114 · 2023 · External reference

EGFR-targeted metal chelating polymers (MCPs) harboring multiple pendant PEG2K chains for MicroPET/CT imaging of patient-derived pancreatic cancer xenografts

10.1021/acsbiomaterials.6b00649 · 2017 · External reference

EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

10.1186/s41181-021-00149-6 · 2021 · External reference

Unresolved reference

2018 · External reference

Fc-engineered monoclonal antibodies to reduce off-target liver uptake

10.1186/s13550-023-01030-0 · 2023 · External reference

Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging

10.1021/bc500111t · 2014 · External reference

PET/CT and SPECT/CT imaging of HER2-positive breast cancer

10.3390/jcm12154882 · 2023 · External reference

Unresolved reference

2015 · External reference

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors

10.1016/j.esmoop.2025.105905 · 2025 · External reference

Basic and practical concepts of radiopharmaceutical purification methods

10.1016/j.drudis.2018.09.018 · 2019 · External reference

Effect of modulating FcRn binding on direct and pretargeted tumor uptake of full-length antibodies

10.1158/1535-7163.mct-19-1015 · 2020 · External reference

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

10.1007/s00259-002-1090-0 · 2003 · External reference

Enzyme‐mediated site‐specific bioconjugation of metal complexes to proteins: sortase‐mediated coupling of copper‐64 to a single‐chain antibody

10.1002/anie.201402613 · 2014 · External reference

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging

10.1007/s00259-009-1263-1 · 2009 · External reference

10.1016/j.bbcan.2021.188529

10.1016/j.bbcan.2021.188529 · External reference

Individualization of radionuclide therapies: challenges and prospects

10.3390/cancers14143418 · 2022 · External reference

Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release

10.1039/d3sc04324j · 2024 · External reference

Template directed synthesis of antibody Fc conjugates with concomitant ligand release

10.1039/d1sc06182h · 2022 · External reference

Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells

10.1084/jem.20161950 · 2017 · External reference

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years

10.1007/s00277-022-04781-3 · 2022 · External reference

225Ac α-pretargeted radioimmunotherapy of human epidermal growth factor receptor 2–expressing breast cancer

10.2967/jnumed.125.269601 · 2025 · External reference

HER3 PET imaging: 68Ga-labeled affibody molecules provide superior HER3 contrast to 89Zr-labeled antibody and antibody-fragment-based tracers

10.3390/cancers13194791 · 2021 · External reference

Antibody engineering for nuclear imaging and radioimmunotherapy

10.2967/jnumed.122.263861 · 2022 · External reference

Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations

10.1073/pnas.83.8.2632 · 1986 · External reference

Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept

10.7150/thno.35461 · 2019 · External reference

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

10.1158/1078-0432.ccr-10-0382 · 2010 · External reference

Highly reactive trans-cyclooctene tags with improved stability for diels–alder chemistry in living systems

10.1021/bc400153y · 2013 · External reference

GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer

10.7150/thno.107209 · 2025 · External reference

DFO-Km: a modular chelator as a new chemical tool for the construction of zirconium-89-based radiopharmaceuticals

10.1021/acs.inorgchem.3c02714 · 2023 · External reference

Synthesis and evaluation of bifunctional DFO2K: a modular chelator with ideal properties for zirconium-89 chelation

10.1039/d4dt01830c · 2024 · External reference

10.7150/thno.79976

10.7150/thno.79976 · External reference

Evaluation of 177Lu-labeled pertuzumab F(ab′) 2 fragments for HER2-positive cancer targeting: a comparative in vitro and in vivo study

2024 · External reference

A systematic evaluation of antibody modification and 89Zr-radiolabeling for optimized immuno-PET

10.1021/acs.bioconjchem.0c00087 · 2020 · External reference

Influence of Fc modifications and IgG subclass on biodistribution of humanized antibodies targeting L1CAM

10.2967/jnumed.121.262383 · 2022 · External reference

Nuclear medicine and wall street: an evolving relationship

10.2967/jnumed.118.220798 · 2019 · External reference

Development of a [89Zr]Zr-labeled human antibody using a novel phage-displayed human scFv library

10.1158/1078-0432.ccr-23-3647 · 2024 · External reference

Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications

10.1021/bc100586y · 2011 · External reference

EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials

10.1007/s00259-024-06640-x · 2024 · External reference

New bifunctional chelator 3p-C-NEPA for potential applications in Lu(III) and Y(III) radionuclide therapy and imaging

10.1021/acsomega.0c03551 · 2020 · External reference

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer

2026 · External reference

Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation

10.1093/protein/gzu030 · 2014 · External reference

Localization, mechanism and reduction of renal retention of technetium‐99m labeled epidermal growth factor receptor‐specific nanobody in mice

10.1002/cmmi.408 · 2010 · External reference

10.1158/0008-5472.can-06-1630

10.1158/0008-5472.can-06-1630 · External reference

10.1021/acs.molpharmaceut.1c00841

10.1021/acs.molpharmaceut.1c00841 · External reference

The influence of glycans-specific bioconjugation on the FcγRI binding and in vivo performance of 89Zr-DFO-pertuzumab

10.7150/thno.39089 · 2020 · External reference

The impact of FcγRI binding on immuno-PET

10.2967/jnumed.118.223636 · 2019 · External reference

Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging

10.1002/jlcr.3628 · 2018 · External reference

Radionuclide therapy of HER2-expressing human xenografts using affibody-based peptide nucleic acid–mediated pretargeting: in vivo proof of principle

10.2967/jnumed.118.208348 · 2018 · External reference

Shorter peptide nucleic acid probes improve affibody-mediated peptide nucleic acid-based pretargeting

10.1021/acsptsci.4c00106 · 2024 · External reference

Synthesis of site-specific radiolabeled antibodies for radioimmunotherapy via genetic code expansion

10.1021/acs.bioconjchem.6b00412 · 2016 · External reference

Good practices for (89)Zr radiopharmaceutical production and quality control

10.1186/s41181-024-00258-y · 2024 · External reference

10.2967/jnumed.112.111021

10.2967/jnumed.112.111021 · External reference

Harnessing α-emitting radionuclides for therapy: radiolabeling method review

10.2967/jnumed.121.262687 · 2022 · External reference

Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry

10.1021/bc400122c · 2013 · External reference

Carrier systems of radiopharmaceuticals and the application in cancer therapy

2024 · External reference